Showing 3301-3310 of 7638 results for "".
- L’Oréal Rewards Social Initiatives Led By Dermatologists at WCDhttps://practicaldermatology.com/news/loreal-rewards-social-initiatives-led-by-dermatologists-at-wcd/2460073/In partnership with the International League of Dermatological Societies (ILDS) and the 24th World Congress of Dermatology (WCD), L’Oréal announced the laureates of the third International Awards for Social Responsibility in Dermatology: “Caring to Inspire Skin Confidence”. This aims to reward soc…
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue to talk about acne and share her Proactiv journey …
- Joanna Zucker is New CEO at PCA Skinhttps://practicaldermatology.com/news/joanna-zucker-is-new-ceo-at-pca-skin/2460071/With more than 25 years of experience in Consumer Packaged Goods and Retail, Joanna Zucker is assuming the role of Chief Executive Officer for PCA SKIN, part of Colgate-Palmolive's professional skin care portfolio. Ms. Zucker previously served in senior management and marketing roles at PetSmart a…
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly Translucent Gel Sunscree…
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary endpoint at week 24,…
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, randomis…
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Dermatolo…
- Gillette Skin Guard Reduces Razor Bumps by 60%https://practicaldermatology.com/news/gillette-skin-guard-reduces-razor-bumps-by-60/2460065/Gillette’s recently launched SkinGuard razor is helping men who are susceptible to razor bumps, also known as Pseudofolliculitis barbae or PFB, new research shows. Results from a recent clinical study from Wake Forest University revealed that the incidence of men’s razor bumps was reduced on ave…
- Data Show 2-Year Complete Response with AbbVie's Skyrizi: WCDhttps://practicaldermatology.com/news/data-show-2-year-complete-response-with-abbvies-skyrizi-wcd/2460064/New results presented by AbbVie show that a significant number of patients treated with Skyrizi™ (risankizumab) experienced complete skin clearance at week 94. These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adult patients w…
- Burt's Bees Data at WCD Highlights Power of Naturalshttps://practicaldermatology.com/news/burts-bees-data-at-wcd-highlights-power-of-naturals/2460062/New research from Burt's Bees supports findings related to the skin's composition and the role of nature-based regimens to protect the skin against common environmental stressors. The studies will be presented at the 24th World Congress of Dermatology (WCD) Meeting in Milan, Italy, June 10-15, 2019…